ImmunoPrecise Antibodies Ltd. (IPA): Price and Financial Metrics
GET POWR RATINGS... FREE!
IPA Stock Summary
- IMMUNOPRECISE ANTIBODIES LTD's stock had its IPO on December 31, 2020, making it an older stock than merely 8.96% of US equities in our set.
- For IPA, its debt to operating expenses ratio is greater than that reported by only 8.39% of US equities we're observing.
- With a year-over-year growth in debt of -67.38%, IMMUNOPRECISE ANTIBODIES LTD's debt growth rate surpasses just 3.39% of about US stocks.
- Stocks that are quantitatively similar to IPA, based on their financial statements, market capitalization, and price volatility, are KMPH, ONTO, CDE, EBS, and ASTS.
- Visit IPA's SEC page to see the company's official filings. To visit the company's web site, go to www.immunoprecise.com.
IPA Stock Price Chart Interactive Chart >
IPA Price/Volume Stats
|Current price||$5.03||52-week high||$6.86|
|Prev. close||$5.04||52-week low||$3.51|
|Day high||$5.09||Avg. volume||22,672|
|50-day MA||$4.86||Dividend yield||N/A|
|200-day MA||$4.85||Market Cap||125.42M|
ImmunoPrecise Antibodies Ltd. (IPA) Company Bio
ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.
Most Popular Stories View All
IPA Latest News Stream
|Loading, please wait...|
IPA Latest Social Stream
View Full IPA Social Stream
Latest IPA News From Around the Web
Below are the latest news stories about IMMUNOPRECISE ANTIBODIES LTD that investors may wish to consider to help them evaluate IPA as an investment opportunity.
VICTORIA, British Columbia, October 12, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), today announced that its subsidiary, Talem Therapeutics LLC ("Talem"), has entered into a multi-target license agreement with OmniAb, Inc., a subsidiary of Ligand Pharmaceuticals Incorporated. The agreement builds upon Talem’s extensive antibody development expertise and its access to LENSai™ in silico software technology to further the development and commerciali
NIAID Confirms IPA’s PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75
VICTORIA, British Columbia, September 14, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), announced today that its subsidiary, Talem Therapeutics LLC ("Talem"), has shared positive results of a new study conducted by the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), that has shown the continued resilience of PolyTope® TATX-03 in broadly neutralizing SARS-Co-V-2 variants, including two O
VICTORIA, British Columbia, September 14, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced financial results for first quarter fiscal year 2023, which ended July 31, 2022.
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022
VICTORIA, British Columbia, September 08, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2023, on Wednesday, September 14, 2022, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call.
Live Virus Assays at Ludwig-Maximilians-Universität München Confirm PolyTope’s Efficacy Against SARS-CoV-2 Variants Including BA.5
VICTORIA, British Columbia, August 29, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), a biotherapeutic research and technology company, today announced the continuing success of PolyTope® TATX-03 antibody combination therapy to neutralize variants of concern of the COVID-19 causative virus, including the latest Omicron BA.5 subvariant, validated by an independent research organization in an authentic virus assay.
IPA Price Returns